Partial response of pulmonary adenocarcinoma with symptomatic brain metastasis to nivolumab plus high-dose oral corticosteroid: a case report
Hélène Pluchart, Julian Pinsolle, Julien Cohen et al. · Journal of Medical Case Reports · 2017
BACKGROUND: Nivolumab, a monoclonal antibody targeting the programmed death-1 receptor, is indicated in locally advanced or metastatic non-small cell lung cancer, with progression after platinum-based chemotherapy. Up-to-now, few data are available concerning brain activity of this treatment and concomitant use of corticosteroids. CASE PRESENTATION: A 64-year-old caucasian man with a pulmonary adenocarcinoma associated with brain metastases received four courses of nivolumab in concomitance with a high dose of corticosteroids for his neurologic symptoms. He experienced a partial response in his brain and chest with an improvement in his general condition. Nivolumab was effective in shrinking symptomatic brain metastases, and metastases at other sites, in a patient with non-small cell lung cancer and first-line chemotherapy failure. The effect of nivolumab was obtained despite concomitant high-dose corticosteroid therapy. Combined nivolumab and high-dose corticosteroid therapy did not induce unexpected adverse events. CONCLUSION: Nivolumab and concomitant high-dose corticosteroid therapy was found to be efficient and well tolerated.
Cited by 11 works. doi:10.1186/s13256-017-1334-z Open-access PDF
Authors
- Hélène Pluchart
- Julian Pinsolle
- G. Ferretti
- Pierrick Bedouch
- Matteo Giaj Levra
- Anne‐Claire Toffart
- Denis Moro‐Sibilot
References
- Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial
- NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 4.2016
- Nivolumab in NSCLC: latest evidence and clinical potential
- Systemic Immunotherapy for the Treatment of Brain Metastases
- Severe exacerbation or manifestation of primary disease related to nivolumab in non-small-cell lung cancer patients with poor performance status or brain metastases
- Ipilimumab and Bevacizumab in Glioblastoma
- Systemic Therapies in the Treatment of Non-Small-Cell Lung Cancer Brain Metastases